COVID-19 and Cardiovascular Disease

By K. Clerkin, J. Fried, J. Raikhelkar, G. Sayer, J. Griffin, A. Masoumi, Sneha S. Jain, D. Burkhoff, D. Kumaraiah, L. Rabbani and 2 more. Circulation, 2020

1,516 citations recorded by the source corpus.

Coronavirus disease 2019 (COVID-19) is a global pandemic affecting 185 countries and >3 000 000 patients worldwide as of April 28, 2020. COVID-19 is caused by severe acute respiratory syndrome coronavirus 2, which invades cells through the angiotensin-converting enzyme 2 receptor. Among patients with COVID-19, there is a high prevalence of cardiovascular disease, and >7% of patients experience myocardial injury from the infection (22% of critically ill patients). Although angiotensin-converting enzyme 2 serves as the portal for infection, the role of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers requires further investigation. COVID-19 poses a challenge for heart transplantation, affecting donor selection, immunosuppression, and posttransplant management. There are a number of promising therapies under active investigation to treat and prevent COVID-19.

Subfields: Infectious Diseases, Neurology

View Paper: https://www.semanticscholar.org/paper/da0ec45551c41eea1a8f414366cf47ae7b0e61ef

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. Bhurint Siripanthong
2. L. Cooper
3. C. Chahal
4. D. Muser
5. R. Deo
6. M. Khanji
7. P. Santangeli
8. S. Nazarian

Citations in the corpus

• Recognizing COVID-19–related myocarditis: The possible pathophysiology and proposed guideline for diagnosis and management (2020, background): “However, many COVID-19 patients were reported to have a detectable level of cTnI, even when they had no overt cardiac symptoms(38) and the finding does not generally represent type 1 myocardial infarction.(39) It is possible that the raised troponin level is a result of an exacerbation of the patien”